We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adaptive Biotechnologies (ADPT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adaptive Biotechnologies is one of 987 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ADPT has gained about 96.8% so far this year. In comparison, Medical companies have returned an average of -3.1%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Anavex Life Sciences (AVXL - Free Report) . The stock is up 0.5% year-to-date.
For Anavex Life Sciences, the consensus EPS estimate for the current year has increased 24.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, a group that includes 495 individual companies and currently sits at #85 in the Zacks Industry Rank. On average, this group has lost an average of 1.1% so far this year, meaning that ADPT is performing better in terms of year-to-date returns. Anavex Life Sciences is also part of the same industry.
Adaptive Biotechnologies and Anavex Life Sciences could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adaptive Biotechnologies (ADPT - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Adaptive Biotechnologies is one of 987 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adaptive Biotechnologies is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ADPT's full-year earnings has moved 5.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, ADPT has gained about 96.8% so far this year. In comparison, Medical companies have returned an average of -3.1%. This means that Adaptive Biotechnologies is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Anavex Life Sciences (AVXL - Free Report) . The stock is up 0.5% year-to-date.
For Anavex Life Sciences, the consensus EPS estimate for the current year has increased 24.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry, a group that includes 495 individual companies and currently sits at #85 in the Zacks Industry Rank. On average, this group has lost an average of 1.1% so far this year, meaning that ADPT is performing better in terms of year-to-date returns. Anavex Life Sciences is also part of the same industry.
Adaptive Biotechnologies and Anavex Life Sciences could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.